The Pharma Data

AUGUST 17, 2021

About JEMPERLI (dostarlimab-gxly) JEMPERLI is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. The collaboration has resulted in three monospecific antibody therapies that have progressed into the clinic. Immune-Mediated Pneumonitis.

FDA Approval 52

FDA Approval Antibody DNA Hormones 52

The Pharma Data

JULY 23, 2021

Evaluate clinical chemistries including liver enzymes, creatinine, adrenocorticotropic hormone (ACTH) level, and thyroid function at baseline and periodically during treatment with OPDIVO and before each dose of YERVOY. endocrinopathies and dermatologic reactions) are discussed below.

Hormones 52

Hormones Trials Genomics Genome 52

The Pharma Data

MARCH 11, 2021

Evaluate clinical chemistries including liver enzymes, creatinine, adrenocorticotropic hormone (ACTH) level, and thyroid function at baseline and periodically during treatment with OPDIVO and before each dose of YERVOY. endocrinopathies and dermatologic reactions) are discussed below. Immune-Mediated Dermatologic Adverse Reactions.

Trials 52

Trials Hormones Genomics Genome 52

The Pharma Data

AUGUST 3, 2021

We expect that recovery in the dermatology segment will continue to progress over the coming quarters. For the remainder of the year, we expect continued growth from Kyprolis use in combination with CD38 antibodies. Looking forward, we are preparing for the anticipated approval of the mild-to-moderate psoriasis indication in the U.S.,

Sales 52

Sales Production Antibody Development 52

XTalks

AUGUST 2, 2023

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. It is a CDK 4/6 inhibitor that is taken in combination with other hormonal therapies to stop the growth of cancer and healthy cells. billion in 2022.

Sales 93

Sales Manufacturing FDA Approval Life Science 93

The Pharma Data

AUGUST 11, 2020

Evaluate clinical chemistries including liver enzymes, creatinine, adrenocorticotropic hormone (ACTH) level, and thyroid function at baseline and before each dose. Institute hormone replacement therapy for endocrinopathies as warranted. Administer hormone-replacement therapy for hypothyroidism. Immune-Mediated Pneumonitis.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

Evaluate clinical chemistries including liver enzymes, creatinine, adrenocorticotropic hormone (ACTH) level, and thyroid function at baseline and before each dose. Institute hormone replacement therapy for endocrinopathies as warranted. Administer hormone-replacement therapy for hypothyroidism. Immune-Mediated Pneumonitis.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52